JP7153669B2 - 瘢痕性眼炎症障害の治療のためのコバーシン - Google Patents

瘢痕性眼炎症障害の治療のためのコバーシン Download PDF

Info

Publication number
JP7153669B2
JP7153669B2 JP2019556909A JP2019556909A JP7153669B2 JP 7153669 B2 JP7153669 B2 JP 7153669B2 JP 2019556909 A JP2019556909 A JP 2019556909A JP 2019556909 A JP2019556909 A JP 2019556909A JP 7153669 B2 JP7153669 B2 JP 7153669B2
Authority
JP
Japan
Prior art keywords
seq
protein
covacine
amino acid
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019556909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517643A5 (enExample
JP2020517643A (ja
Inventor
エイチ． ウェストン－デービス，ウィン
Original Assignee
ヴォリューション イミュノ ファーマシューティカルズ エスエイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1706406.4A external-priority patent/GB201706406D0/en
Priority claimed from GBGB1706398.3A external-priority patent/GB201706398D0/en
Application filed by ヴォリューション イミュノ ファーマシューティカルズ エスエイ filed Critical ヴォリューション イミュノ ファーマシューティカルズ エスエイ
Publication of JP2020517643A publication Critical patent/JP2020517643A/ja
Publication of JP2020517643A5 publication Critical patent/JP2020517643A5/ja
Priority to JP2022159216A priority Critical patent/JP2022188170A/ja
Application granted granted Critical
Publication of JP7153669B2 publication Critical patent/JP7153669B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2019556909A 2017-04-21 2018-04-20 瘢痕性眼炎症障害の治療のためのコバーシン Active JP7153669B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022159216A JP2022188170A (ja) 2017-04-21 2022-10-03 瘢痕性眼炎症障害の治療のためのコバーシン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment
GBGB1706398.3A GB201706398D0 (en) 2017-04-21 2017-04-21 Method of treatment
GB1706398.3 2017-04-21
GB1706406.4 2017-04-21
PCT/EP2018/060239 WO2018193120A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of cicatrising eye inflammatory disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022159216A Division JP2022188170A (ja) 2017-04-21 2022-10-03 瘢痕性眼炎症障害の治療のためのコバーシン

Publications (3)

Publication Number Publication Date
JP2020517643A JP2020517643A (ja) 2020-06-18
JP2020517643A5 JP2020517643A5 (enExample) 2021-05-27
JP7153669B2 true JP7153669B2 (ja) 2022-10-14

Family

ID=62028030

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556909A Active JP7153669B2 (ja) 2017-04-21 2018-04-20 瘢痕性眼炎症障害の治療のためのコバーシン
JP2022159216A Ceased JP2022188170A (ja) 2017-04-21 2022-10-03 瘢痕性眼炎症障害の治療のためのコバーシン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022159216A Ceased JP2022188170A (ja) 2017-04-21 2022-10-03 瘢痕性眼炎症障害の治療のためのコバーシン

Country Status (8)

Country Link
US (1) US20210113658A1 (enExample)
EP (1) EP3612206A1 (enExample)
JP (2) JP7153669B2 (enExample)
KR (1) KR20190138650A (enExample)
CN (1) CN110831617A (enExample)
AU (1) AU2018253960A1 (enExample)
CA (1) CA3060331A1 (enExample)
WO (1) WO2018193120A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
AU2019468121A1 (en) 2019-09-27 2022-05-12 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
JP7736925B2 (ja) 2022-05-18 2025-09-09 旭化成株式会社 樹脂組成物の製造方法
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020517627A (ja) 2017-04-21 2020-06-18 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
JP2020517260A (ja) 2017-04-21 2020-06-18 ヴォリューション イミュノ ファーマシューティカルズ エスエイ Ｃ５結合性を欠失したコバーシンバリアント

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
JP2010502687A (ja) * 2006-09-08 2010-01-28 ヴァーレイ・リミテッド 呼吸器疾患の治療方法
EA200901211A1 (ru) * 2007-03-22 2010-04-30 Новартис Аг Антигены белка с5 и их применение
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2011056972A2 (en) * 2009-11-04 2011-05-12 Case Western Reserve University Compositions and methods of treating a t cell mediated disorder
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
ES3044832T3 (en) * 2011-06-22 2025-11-27 Apellis Pharmaceuticals Inc Methods of treating chronic disorders with complement inhibitors
US20170014487A1 (en) * 2014-03-04 2017-01-19 The Trustees Of Columbia University In The City Of New York Method for treating ocular inflammation
GB201410031D0 (en) * 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
US9937222B2 (en) * 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020517627A (ja) 2017-04-21 2020-06-18 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
JP2020517260A (ja) 2017-04-21 2020-06-18 ヴォリューション イミュノ ファーマシューティカルズ エスエイ Ｃ５結合性を欠失したコバーシンバリアント

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Drug Discovery & Development [オンライン], 2016, [検索日：2021.12.14]，インターネット<URL:https://www.drugdiscoverytrends.com/coversin-a-novel-complement-inhibitor-for-inflammatory-and-autoimmune-disease/>
Investigative Ophthalmology & Visual Science, July 2018, Vol. 59, ARVO Annual Meeting Abstract No. 507
JCI Insight, 2016, 1 (12), e87012
JCI Insight, 2016, 1(12), e87001

Also Published As

Publication number Publication date
CN110831617A (zh) 2020-02-21
KR20190138650A (ko) 2019-12-13
WO2018193120A1 (en) 2018-10-25
AU2018253960A1 (en) 2019-10-31
US20210113658A1 (en) 2021-04-22
JP2022188170A (ja) 2022-12-20
JP2020517643A (ja) 2020-06-18
EP3612206A1 (en) 2020-02-26
CA3060331A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
JP7153669B2 (ja) 瘢痕性眼炎症障害の治療のためのコバーシン
US20240009270A1 (en) Coversin for the treatment of autoimmune blistering diseases
EP2061501B1 (en) Method of treating respiratory disorders
CN101340926A (zh) 治疗重症肌无力的方法
JP7603612B2 (ja) 治療法
JP6087429B2 (ja) 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途
US6800290B2 (en) Variants of allergenic proteins of the group 2 of dermatophagoides
TWI889483B (zh) 具有改善乾眼症活性的新型胜肽及包括其之藥物組合物
WO2024115767A1 (en) Nomacopan-pas fusion proteins
DK2061501T3 (en) METHOD OF TREATING RESPIRATORY DISORDERS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220831

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221003

R150 Certificate of patent or registration of utility model

Ref document number: 7153669

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150